Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
December 18, 2019
SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis
Kai Su Greene, Michael J Lukey, Xueying Wang, et al.
Cancer Research
|
November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
A Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Cancer Research
|
December 18, 2021
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors
Clint A Stalnecker, Kajal R Grover, A Cole Edwards, et al.
Cancer Research Communications
|
July 9, 2026
Acquisition of resistance to RAS inhibition is associated with the upregulation of macropinocytosis through both PI3K-dependent and -independent signaling
Ryan Robb, Sarah E Ackermann, Seamus E Degan, et al.
Biorxiv : the Preprint Server for Biology
|
January 23, 2026
Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance
Kristina Drizyte-Miller, Seamus E Degan, Ryan D Mouery, et al.
Biorxiv : the Preprint Server for Biology
|
May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer
Wen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
Cancer Research
|
February 11, 2025
Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Jonathan M DeLiberty, Mallory K Roach, Clint A Stalnecker, et al.
Cancer Research
|
November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
Craig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Cancer Research
|
July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Cancer Research
|
November 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer
Szu-Aun Long, Haley Todd, Grace Goodhart, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
Proceedings of the National Academy of Sciences of the United States of America
|
December 18, 2019
SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis
Kai Su Greene, Michael J Lukey, Xueying Wang, et al.
Cancer Research
|
November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
A Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Cancer Research
|
December 18, 2021
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors
Clint A Stalnecker, Kajal R Grover, A Cole Edwards, et al.
Cancer Research Communications
|
July 9, 2026
Acquisition of resistance to RAS inhibition is associated with the upregulation of macropinocytosis through both PI3K-dependent and -independent signaling
Ryan Robb, Sarah E Ackermann, Seamus E Degan, et al.
Biorxiv : the Preprint Server for Biology
|
January 23, 2026
Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance
Kristina Drizyte-Miller, Seamus E Degan, Ryan D Mouery, et al.
Biorxiv : the Preprint Server for Biology
|
May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer
Wen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
Cancer Research
|
February 11, 2025
Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Jonathan M DeLiberty, Mallory K Roach, Clint A Stalnecker, et al.
Cancer Research
|
November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
Craig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Cancer Research
|
July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Cancer Research
|
November 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer
Szu-Aun Long, Haley Todd, Grace Goodhart, et al.
Page
of 3